The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA

NARecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

January 1, 2026

Conditions
Refractory Aplastic Anemia
Interventions
DRUG

avatrombopag

Avatrombopag, 40-60 mg (body weight \< 80 kg, 40 mg per day; body weight \> 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

collaborator

Xiyuan Hospital of China Academy of Chinese Medical Sciences

OTHER

collaborator

Second Hospital of Shanxi Medical University

OTHER

collaborator

First Affiliated Hospital of Harbin Medical University

OTHER

collaborator

The First Hospital of Hebei Medical University

OTHER

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER